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Impact Statement: The manuscript demonstrates VASP Ser239 phosphorylation
opposes malignant cell shape promoting invasion in colon cancer cells. Induction of
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VASP Ser239 phosphorylation may represent an innovative intervention to prevent tumor
progression and metastasis in patients with colorectal cancer.
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ABSTRACT
In colorectal cancer, the antitumorigenic guanylyl cyclase C (GCC) signalome is
defective reflecting ligand deprivation from downregulation of endogenous hormone
expression. Although the proximal intracellular mediators of that signal transduction
system, including cyclic guanosine monophosphate (cGMP) and cGMP-dependent
protein kinase (PKG), are well characterized, the functional significance of its distal
effectors remain vague.

Dysregulation of ligand-dependent GCC signaling through

vasodilator-stimulated phosphoprotein (VASP), an actin-binding protein implicated in
membrane

protrusion

dynamics,

drastically

reduced

phosphorylation levels in colorectal tumors from patients.

cGMP-dependent

VASP

Restoration of cGMP-

dependent VASP phosphorylation by GCC agonists suppressed the number and length of
locomotory (filopodia) and invasive (invadopodia) actin-based organelles in human colon
cancer cells. Membrane organelle disassembly reflected specific phosphorylation of
VASP Ser239, the cGMP/PKG preferred site, and rapid VASP removal from tumor cell
protrusions.

Importantly, VASP Ser239 phosphorylation inhibited the proteolytic

function of invadopodia, reflected by suppression of the cancer cell ability to digest DQcollagen IV embedded in Matrigel. These results demonstrate a previously unrecognized
role for VASP Ser239 phosphorylation, a single intracellular biochemical reaction, as an
effective mechanism which opposes tumor cell shape promoting colon cancer invasion
and metastasis. Reconstitution of physiological cGMP circuitry through VASP, in turn,
represents an attractive targeted approach for patients with colorectal cancer.
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INTRODUCTION
Despite considerable advancements in elucidating pathognomonic genetic and molecular
alterations, the causal mechanisms underlying initiation and progression of colorectal
cancer, the third most common and deadly neoplasm in the western world, remain
unknown.

In the paracrine hormone hypothesis of colon cancer,1 tumorigenesis is

characterized by a state of guanylyl cyclase C (GCC) ligand insufficiency, in which
expression of endogenous hormones guanylin and uroguanylin, secreted by and
activating GCC receptors on intestinal epithelial cells in an autocrine and paracrine
fashion, is dramatically reduced following a yet unidentified event early during
transformation.2-3 Ligand-induced GCC activation physiologically regulates intestinal
fluid and electrolyte homeostasis through intracellular accumulation of the second
messenger cyclic guanosine monophosphate (cGMP) and cGMP-dependent protein
kinase (PKG) phosphorylation of ion channels.4 Activation of GCC also promotes the
transition from the proliferative crypt phenotype to the differentiated colonocyte along
intestinal mucosal surfaces by imposing cytostasis5 and oxidative metabolic
reprogramming,6
antitumorigenesis.7

effects

presumably

underlying

GCC-mediated

colorectal

Thus, the GCC ligandopenia associated with neoplastic

transformation may promote colorectal carcinogenesis by producing a repressed GCC
and cGMP pathway devoid of tumor suppressor activities.

However, the exact

consequences at the molecular level of the absence of GCC activation in colon cancer
cells are unclear.
A poorly investigated target for the antitumorigenic GCC pathway is the vasodilatorstimulated phosphoprotein (VASP).8 A mammalian member of the highly conserved
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Ena/VASP family proteins, VASP acts as a molecular scaffold to bring together growing
actin filaments with regulatory proteins at the cell leading edge.9 VASP controls cell
spreading and migration by regulating the formation and stability of protrusive membrane
structures driven by actin polymerization, including lamellipodia and filopodia, and the
integrity of cell-matrix interactions at adhesion complexes.9 In that context, VASP exerts
a pivotal role in filopodial dynamics, reflected by its localization at the filopodial tip
complex where it promotes filopodia formation and elongation by recruiting the initial
nanomachinery and imposing anti-capping pressure on actin filament barbed ends.10
Three critical domains mediates VASP/actin interactions:9 1) the Ena/VASP homology 1
(EVH1) domain at the N-terminus, which binds to proteins with poly-proline II helix,
including vinculin and zyxin; 2) the central prolin-rich region, which binds to proteins
containing SH3 and WW domains and the globular (G)-actin binding profilin, and 3) the
EVH2 domain at the C-terminus, which binds to both G- and filamentous (F)-actin and
mediates VASP oligomerization, thereby promoting F-actin bundling and stabilization.
Importantly, VASP harbors 3 phosphorylation sites (Ser157, Ser239 and Thr278) which
are targeted with different affinities by PKG, cAMP-dependent protein kinase and AMPactivated protein kinase, and modulate its localization and function.11-13 Phosphorylation
of VASP Ser239, adjacent to the G-actin binding site in the EVH2 domain, is selectively
regulated by cGMP-dependent signaling through PKG,11 an event that disrupts VASP
anti-capping and filament-bundling activities and inhibits membrane protrusion
formation.9, 14
While its engagement in migration and membrane protrusion dynamics in normal cells is
well-established, a similar role for VASP Ser phosphorylation in cancer cells has not

5

emerged.

However, actin cytoskeletal remodeling at dynamic membrane regions

determines oncogenic behaviors, from epithelial-to-mesenchymal transition to tissue
invasion and metastasis.15-16 In principle, PKG-mediated VASP phosphorylation could
represent one of the biochemical reactions of the antitumorigenic GCC/cGMP
signalome.1

Here, human colon tumors exhibited reduced GCC ligand expression

associated with depletion of cGMP-dependent VASP phosphorylation, indicating
interruption of downstream signaling by the dysregulated GCC pathway. Restoration of
cGMP-mediated phosphorylation of VASP Ser239 by ligand-induced GCC signaling
suppressed the invasive cancer cell phenotype, with disassembly of protrusive membrane
organelles (filopodia, invadopodia) and inability to promote DQ-collagen IV degradation.
Together, these observations reveal a previously unrecognized suppressor of invasive
membrane protrusions and therapeutic target, VASP Ser239 phosphorylation, for
colorectal cancer.
MATERIAL AND METHODS
Reagents. ST was prepared as described,5 while 8-br-cGMP was obtained from SigmaAldrich (St. Louis, MO). Antibodies to human VASP, phosphorylated VASP at Ser157,
GAPDH, villin and cortactin were from Santa Cruz Biotechnology (Santa Cruz, CA).
Two anti-phoshorylated VASP at Ser239 antibodies were purchased, including clone
16C2 from Abcam (Cambridge, MA) and a rabbit antibody from Sigma-Aldrich. The
anti-human guanylin antibody was from BioDesign International (Saco, ME), while the
anti-human PKG was obtained from Assay Designs (Ann Arbor, MI). The antibody to
the human GCC was obtained from Rockland Immunochemicals (Gilbertsville, PA).
DQ-collagen IV, Alexa fluor 555 anti-rabbit IgG, Alexa fluor 633 anti-mouse IgG,
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Oregon Green 488 phalloidin and Slowfade Gold with DAPI were obtained from
Invitrogen (Carlsbad, CA).

Matrigel was from BD Bioscience (Bedford, MA), the

general matrix metalloproteinase (MMP) inhibitor GM1006 from Calbiochem (San
Diego, CA), and all the reagents for cell culture from Mediatech Inc. (Herndon, VA).
Clinical specimens and immunohistochemistry. Paraffin-embedded specimens from 7
patients

(Supporting

Information

Table

1)

with

histologically-confirmed

adenocarcinomas of the colo-rectum were obtained from the Department of Pathology,
Anatomy and Cell Biology of Thomas Jefferson University (Philadelphia, PA) under a
protocol

approved

by

the

immunohistochemistry (IHC).

Institutional

Review

Board

and

subjected

to

Briefly, following deparaffinization and rehydratation

(with xylene/ethanol/water washes), antigens in tissue sections (5 μm) were unmasked by
two consecutive heating cycles (100°C for 5 min in 10 mM citric buffer, pH 6.0). Then,
specimens were incubated overnight (4°C) with antibodies (1:100 dilution, unless
otherwise indicated) against either human guanylin, GCC, PKG, VASP, and
phosphorylated VASP at Ser157 or Ser239 followed by incubation with the respective
secondary antibody and DAB substrate (Avidin-biotin kit; Vector Laboratory,
Burlingame, CA). Staining intensity was quantified by a blinded pathologist on a 1 to 3
scale (1, low or absent; 2, medium; 3 high).
Cell culture. All the human colon carcinoma cell lines investigated were purchased from
the American Type Culture Collection (ATCC, Manassas, VA) and used within 6 months
from resuscitation.

Methods of cell authentication by ATCC include analyses of

morphological and growth characteristics, isoenzymology and DNA profiles. T84 and
HCT-116 human colon carcinoma cells were cultured (37°C, 5% CO2) with 10% fetal

7

bovine serum in DMEM/F12 or DMEM, respectively. Cells (2-20 passages) were fed
with fresh medium every third day and split when sub-confluent.
Plasmids and cell transductions. Full length VASP cDNA (Invitrogen, Carlsbad, CA)
was sub-cloned into the Xho1-EcoR1 multiple cloning site of mouse stem cell virus
(MSCV)-puro retroviral vector. Point mutations of VASP serines 157 (tcc → gcc) and
239 (agc → gcc) were performed employing the QuikChange XL Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA) to generate VASP mutants with alanine
substitutions at Ser157 (S157A), Ser239 (S239A) or both (AA).

Green fluorescent

protein (GFP)-VASP constructs were generated by sub-cloning wild type VASP or the
VASP mutant S239A in-frame to the C-terminus of GFP using the pRetroQ-AcGFP-Cl
vector (Stratagene). HEK 293T17 cells (from ATCC) were transfected with 1 µg of each
purified MSCV construct plus 1 µg of the packaging vector pCl-Ampho employing
Fugene transfection reagent (Roche, Basel, Switzerland). T84 cells were transduced (for
72 h) with viral supernatants supplemented with 4 µg/ml polybrene, then selected and
maintained in 5 µg/ml puromycin.

In this way, the following T84 clones stably-

expressing the MSCV-driven gene were generated: VASP, VASP-S157A, VASP-S239A,
VASP-AA, GFP, GFP-VASP and GFP-VASP-S239A.
Immunoblot analysis. Protein samples (40 g in SDS loading buffer) were separated by
electrophoresis on 10% acrylamide Tris-Glycine gels, transferred to nitrocellulose
membranes, and probed (1:1,000 each) with rabbit polyclonal antibodies against VASP,
phosphorylated VASP at Ser157, GAPDH, villin or mouse monoclonal antibody against
phosphorylated VASP at Ser239 in TBS-Tween (5% milk) overnight at 4°C. After
washing the primary antibody, membranes were probed with the appropriate secondary
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antibody (1:2,000) (SantaCruz Biotechnology) for 1 h at room temperature.
Immunostained bands were imaged with a Kodak Image Station 4000R and quantified by
densitometry.
Immunofluorescence and imaging. Filopodia dynamics were studied in cancer cells
cultured on Lab-Tek glass microscope-chambered slides and treated for 2 h with PBS
(control), the GCC ligand ST (1 μM) or the cGMP analog 8-br-cGMP (5 mM).
Invadopodia were examined employing glass coverslips coated with 25 l Matrigel and
incubated at 37°C (10 min) to solidify. Here, cancer cells were plated drop-wise directly
onto Matrigel, allowed to firmly adhere (1 h) and equilibrate (24 h) in their culturing
medium, and finally treated (2 h) with PBS or ST (1 μM). Following treatments, cells
were fixed (15 min) with ice-cold paraformaldehyde (4%, in PBS) and permeabilized (10
min) with 0.1% Triton X-100. Following overnight incubations (4°C; in PBS containing
2% bovine serum albumin) with mouse anti-cortactin and/or rabbit anti-VASP antibodies
(1:100 each) and 5 units/ml Oregon Green 488 phalloidin, cells were incubated (60 min
at room temperature) with Alexa fluor 633 anti-mouse IgG and/or Alexa fluor 555 antirabbit IgG.

Specificity of antigen/antibody reactions was assessed employing the

secondary antibody alone. Some preparations were counterstained with Slowfade Gold
anti-fade reagent with DAPI to identify cell nuclei. Images (63x) were acquired with a
confocal laser scanning microscope (LSM 510, Carl Zeiss, Jena, Germany) equipped with
a monochrome CCD camera and pseudo-colored with image-analysis software.
For filopodia measurements, cells were analyzed by differential interference contrast
(DIC) microscopy. Filopodial protrusions (≥5 M) were examined on 8-10 random cell
colonies per treatment (~50-100 filopodia/treatment) by quantifying the number (per cell
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colony perimeter) and length (the average distance from the cell base to the tip) of
filopodia. The cancer cell colony perimeter (~264 ± 41 M) was determined to ensure
that results from colonies with different sizes could be directly compared. Measurements
were performed using the Zeiss LSM Image Browser software (Carl Zeiss Microimaging,
Thornwood, NY).

For invadopodia analyses, the number and length of individual

invadopodia (the baso-lateral actin-based membrane projections) per cancer cell were
quantified (with the Zeiss LSM Image Browser software) on 8-10 random cells per
treatment from 3-dimensional (3-D) reconstructions created from orthogonal X, Y and Z
sections of complete Z-stack cell images (at 1 μm increments) of the confocal
microscope. Finally, live cell microscopy was performed on culture dishes (fitted on a
heated stage) of GFP-VASP (n=6) or GFP-VASP-S239A (n=7) cells by acquiring timelapse images at 0, 1, 5, 10 and 15 min after treatment with the confocal microscope.
Analysis of filopodia was performed with Image J (NIH, Bethesda, MD). The GFPbased fluorescent signal was quantified at filopodia tips (the distal ¼ of each filopodia),
along the entire length of each filopodium and throughout the cell body, and normalized
to the background fluorescence.
DQ-collagen IV degradation.

Glass coverslips were coated with 20 μl Matrigel

containing 25 μg/ml DQ-collagen IV and incubated at 37°C (10 min) to solidify. Cancer
cells were plated drop-wise directly onto these Matrigel scaffolds, allowed to firmly
adhere (1 h), and treated (24 h) in their culturing medium with PBS or ST (1 μM). Then,
cells were fixed in methanol (-20°C for 15 min) and processed by confocal microscopy to
generate Z-stack images, as described for invadopodia analyses above. DQ-collagen IV
degradation was quantified in 8-10 cells per treatment with the NIH Image J as the mean
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fluorescent intensity of the fluorescent cleavage product (from DQ-collagen IV) over the
cell and pericellular area per cell area. Results were normalized to the background
fluorescence.
Statistical analysis.

Unless otherwise indicated, data are mean ± SEM of ≥3

independent experiments. Statistical analyses were performed with the Student’s t test.
RESULTS
VASP is an intracellular effector of the GCC pathway in colon cancer cells. VASP is
expressed in colon cancer cells (46-kDa band; Supporting Information Fig. 1a) and
distributes to dynamic membrane domains, including cell leading edges (Fig. 1a) and
invadopodia (Fig. 1b), where it colocalizes with cortactin and actin (Fig. 1b, right
panels). Invadopodia identity was confirmed by assessing their ability to focally degrade
DQ-collagen IV (Fig. 1c), a fluorogenic analog of the basement membrane component
collagen IV. In addition, VASP is an intracellular target of ligand-dependent GCC
signaling in human colon cancer cells,8 and the potent GCC agonist ST4 induced rapid
phosphorylation of VASP at both Ser157 and Ser239 (Supporting Information Fig. 1b).
ST effects on VASP were mimicked by the membrane-permeant cGMP analog 8-brcGMP (Fig. 1d-e and Supporting Information Fig. 2a) and blocked by the selective PKG
peptide inhibitor DT217 (Fig. 1e and Supporting Information Fig. 2b), confirming that ST
induces VASP Ser phosphorylation by activating the GCC/cGMP/PKG pathway in
human colon cancer cells.
GCC signaling through VASP is dysregulated in colon cancer. In the human colon,
the GCC pathway is constitutively activated by the paracrine hormone guanylin, which
induces cGMP- and PKG-dependent phosphorylation of specific substrates.1,
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Accordingly, normal colonic mucosa from patients exhibited epithelial cells with VASP
Ser157 and Ser239 phosphorylation in the context of an intact guanylin-VASP signaling
axis (Fig. 2a, upper panel). However, following transformation and loss of endogenous
ligand expression2-3 this GCC pathway becomes dysregulated (Fig. 2a, upper panel).
While GCC and PKG exhibited mixed trends with no significant changes, expression of
guanylin and all the VASP species were significantly reduced in colorectal
adenocarcinomas compared to their respective normal counterparts (Fig. 2a).

Of

significance, VASP phosphorylation at Ser157 and Ser239 were the most compromised
signals of the GCC pathway, reflected by their downregulation in all tumors examined
(Fig. 2a, middle panel) and maximal loss of expression (Fig. 2a, lower panel). Thus, loss
of VASP Ser phosphorylation in colon cancer reflects interruption of effective induction
and transmission of GCC-VASP signaling, beyond the mere changes in VASP expression
(Supporting Information Fig. 3).
VASP Ser239 phosphorylation by GCC activation inhibits cancer cell shape
mediating migration and invasion.

As VASP regulates membrane protrusion

geometry18 and is present at cell leading edges and invadopodia (Fig. 1a-b), the
functional consequences of ligand-dependent GCC signaling through VASP Ser
phosphorylation on the membrane architecture of colon cancer cells were examined.
GCC signaling through cGMP significantly reduced the number and length of migratory
(filopodia; Fig. 2b) and invasive (invadopodia; Fig. 2c) actin-based protrusions.
Filopodia identity was confirmed by specific immunostaining with the filopodia marker
fascin (data not shown).

Importantly, cGMP inhibitory effects were specifically

mediated by induction of VASP Ser239 phosphorylation, as demonstrated by employing
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tumor cells stably expressing distinct VASP phosphomutants (Supporting Information
Fig. 4a). Thus, cancer cells with VASP-S239A or VASP-AA, which contain point
mutations at Ser239 and do not accept phosphorylation at that site (Supporting
Information Fig. 4b), were resistant to GCC-mediated inhibition of filopodia (Fig. 3) and
invadopodia (Fig. 4). In contrast, control cells expressing GFP or overexpressing VASP
and tumor cells with the phosphomutant VASP-S157A, which harbors a point mutation at
Ser157 only and does not accept phosphorylation at that site (Supporting Information Fig.
4b), were sensitive to suppression of filopodia (Fig. 3) and invadopodia (Fig. 4) upon
ligand-dependent GCC signaling.
VASP Ser239 phosphorylation suppresses invasive membrane protrusions by
inducing intracellular VASP redistribution.

The molecular mechanism mediating

inhibition of invasive cell shape by VASP Ser239 phosphorylation was investigated with
live imaging microscopy in cells stably expressing GFP-VASP constructs (Fig. 5). Colon
cancer cells with GFP-VASP, but not mutant cells expressing GFP-VASP-S239A,
exhibited disassembly of filopodia (Fig. 5a) and invadopodia (Fig. 5b) upon liganddependent GCC activation.

Protrusion retraction by GCC (Fig. 5c) reflected rapid

removal of VASP from membrane projections (Fig. 5d), with a calculated half-life of
8.11 min (Supporting Information Fig. 5), and VASP redistribution to inner cell
compartments away from membrane tips (Fig. 5e). However, the GFP-VASP-S239A
mutant (resistant to Ser239 phosphorylation), was insensitive to GCC signaling (Fig. 5c),
and retained its localization (Fig. 5d) and distribution (Fig. 5e) at locomotory membrane
extensions, suggesting that VASP Ser239 phosphorylation represents a disassembly
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signal for invasive migratory organelles by uncoupling VASP from actin-based
microregions at colon cancer cell membranes.
VASP Ser239 phosphorylation prevents DQ-collagen IV degradation by colon
cancer cells. Metastatic cancer dissemination requires degradation and remodeling of the
surrounding environment,19 a malignant attribute conferred to colon cancer cells by their
invadopodia (Fig. 1c). Strikingly, activation of GCC signaling through VASP abolished
the cancer ability to degrade DQ-collagen IV, with similar magnitude to that of a general
inhibitor of MMPs (Fig. 6a), enzymes mediating tumor matrix degradation.20 However,
colon cancer cells with VASP-S239A or VASP-AA, but not VASP-S157A, did continue
to proteolytically digest DQ-collagen IV following ligand-dependent GCC signaling (Fig.
6a), indicating that VASP Ser239 phosphorylation mediates arrest of invadopodiamediated proteolysis by the GCC pathway. Thus, VASP Ser239 phosphorylation is a
unique biochemical reaction that suppresses membrane protrusions promoting tumor
invasion in colorectal cancer (Fig. 6b).
DISCUSSION
The antitumorigenic GCC signalome is deregulated during colorectal transformation
reflecting loss of endogenous ligand expression.1-3

Present findings reveal that this

alteration affects a cGMP-dependent intracellular pathway comprising VASP as the distal
effector, with subsequent silencing of an important biochemical reaction, VASP Ser239
phosphorylation, which opposes malignant cell shape.

Interruption of GCC-VASP

signaling, in turn, results in specific depletion of the VASP phosphospecies, which
represent previously undescribed biomarkers for GCC deregulation and tumorigenesis in
colon cancer. Conversely, restoration of GCC signaling by ligand replacement therapy
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may provide a rationale strategy for reconstituting cGMP-VASP circuitry and preventing
metastasis.

Indeed, ligand-dependent GCC activation compromises motility and

metastasis of colon cancer cells,21 presumably by targeting VASP signaling suppressing
invasive membrane protrusions (Fig. 6b) described herein.
Membrane protrusion extension principally reflects the balance of antagonistic forces at
actin filament barbed ends imposing persistence (anti-capping proteins) or arrest (capping
proteins) of actin polymerization.10 VASP is a critical anti-capping protein that initiates
and maintains dynamic membrane regions by orchestrating a cytoskeletal assembly-line
promoting simultaneous F-actin elongation and bundling.10, 22 In this way, Ena/VASP
family members control migration and membrane protrusion formation underlying
important physio(patho)logical processes, from wound-healing, platelet aggregation and
neural development9 to inflammation, cancer spreading and metastasis.9,

23-24

Accordingly, expression of Ena/VASP proteins positively correlates with disease
progression in patients with lung25 or breast26 cancer, suggesting their involvement in
carcinogenesis and metastasis. The present study underscores the critical role of VASP
in organizing cancer functions associated with the malignant membrane shape. In that
context, although with unclear activities VASP is a molecular component of
invadopodia,27 cancer cell projections mediating focal matrix proteolysis. Here, colon
cancer cells required VASP for invadopodia stability and function, indicating that VASP
maintains the structural integrity of these invasive protrusions. Indeed, intracellular
VASP redistribution and removal from protrusive tips, upon GCC-dependent
phosphorylation, destabilizes actin-driven membrane extensions (Fig. 5) by presumably
depleting actin filament plus-ends of VASP-mediated anti-capping forces,22 resulting in
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protrusion retraction from the persistent actin retrograde flow. Importantly, invadopodia
represent attractive antimetastatic targets since they function as critical hubs of invasive
cell behavior, spatially and temporally organizing the activities of actin nucleators and
regulators (Arp2/3, N-WASP, cortactin), signaling enzymes (Src, Erk1/Erk2, FAK),
adhesive receptors (integrins β1/β3, CD44), and proteases (MT1-MMP, MMP2,
MMP9).27-28 Thus, the ability of cGMP-dependent VASP phosphorylation to dismantle
invadopodia in colon cancer cells (Fig. 4) offers an innovative antiinvadopodial strategy
to be exploited against tumor metastasis in patients.
Tumor suppressors inhibiting metastatic cell dissemination are scarce. Their critical
value resides in the potential to serve as biomarkers to improve clinical staging and
targets to reduce cancer mortality. VASP Ser239 phosphorylation, a simple intracellular
biochemical reaction, could represent a unique invasion suppressor with sophisticated
regulatory dynamics, an inducible mechanism embedded into signal transduction
networks shaping tumor cell metastasis. Further, inhibition of metastasis by VASP
Ser239 phosphorylation could be a general strategy, as VASP is ubiquitously expressed
across human tissues.9 Of significance, cGMP-dependent VASP Ser157 phosphorylation
does not appear to affect the invasive phenotype of colon cancer cells (Figs. 3, 4 and 6).
Since VASP Ser239 is selectively regulated by PKG-dependent phosphorylation,9,
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while VASP Ser157 is a more promiscuous site phosphorylated by PKG, cAMPdependent protein kinase, and protein kinase C-dependent and -independent
mechanisms,11,

29

present observations suggest a unique role of the GCC/cGMP/PKG

pathway in suppressing colorectal cancer invasion through VASP Ser239. Reduced
levels of VASP Ser157 phosphorylation in colon cancer (Fig. 2a), in turn, may reflect
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more complex deregulation of tumor intracellular networks, including cGMP-dependent
and -independent pathways, probably affecting carcinogenetic processes beyond GCCregulated invasive cell shape, a model currently being explored in this laboratory.
Present findings also support the existence of a biological divergence between cGMP and
cAMP signaling on Ena/VASP activities, an established paradigm in neurons where the
cAMP-VASP axis mediates attractive guidance cues by increasing the number and length
of filopodia, while the cGMP/PKG/VASP pathway promotes repulsive guidance cues.3031

However, the precise consequences of cyclic nucleotide signaling through VASP on

the actin cytoskeleton appear to be cell and tissue specific, as demonstrated by identical
cGMP and cAMP inhibitory actions on platelet aggregation, reflecting respective VASP
phosphorylation mechanisms.32 Regardless, VASP Ser239 phosphorylation induced by
cGMP is emerging as a pivotal mechanism mediating VASP redistribution and
disassembly of VASP-regulated membrane protrusions, including filopodia and
lamellipodia.14,

33-34

In that context, Ser239 is strategically located within the EVH2

domain of VASP, immediately adjacent to the G-actin binding site, which localizes
VASP at filopodial tips and coordinates the transfer of profilin-bound G-actin to the
barbed end of the elongating F-actin filament.33

Phosphorylation of VASP Ser239

interferes with EVH2-dependent processes at membrane leading edges, destabilizing
VASP-actin interactions and organelle protrusive dynamics.14,

33

Moreover, VASP

Ser239, but not VASP Ser157, phosphorylation inhibits VASP-driven F-actin
polymerization.13 This study demonstrates VASP Ser239 phosphorylation suppresses the
invasive actin cytoskeleton of tumor cells and represents an unappreciated prototype to be
exploited in innovative diagnostic and therapeutic approaches for colorectal cancer.
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Specifically, ligand-dependent GCC signaling may prevent colon cancer metastasis by
neutralizing oncogenic VASP functions at the invasive cancer front.
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FIGURE LEGENDS
Fig. 1. VASP Ser phosphorylation is induced by GCC activation in colon cancer cells.
(a) Cell leading edges (multi-arrows in upper-left panel) of T84 human colon carcinoma
cells (on 2-D surfaces) were imaged (magnification, 63x) by DIC and confocal
microscopy following immunofluorescent staining with phalloidin (green) and antiVASP antibody (red).

Yellow in merged image indicates F-actin and VASP

colocalization at leading tips.

(b) Representative confocal microscopy images of

invadopodia from T84 cells grown on 3-D Matrigel scaffolds (Matrigel/air interfaces,
dotted lines in top panels). Boxes in cartoons on left indicate visual planes in vertical
(top panels) and horizontal (middle panels) cross-sections from Z-stack images. Cells
were immunofluorescently stained for invadopodial marker cortactin (ref. 27) (blue),
VASP (red) and F-actin (green).

In merged images, white (upper panels) and

coincidence of picks (bottom panels) from distinct fluorescent signals along lines
depicted in middle panels indicate cortactin, VASP and F-actin colocalization.

(c)

Vertical or horizontal (bottom-right) T84 cell cross-sections of confocal microscopy
images obtained as in b. Here, Matrigel contained DQ-collagen IV, which releases a
fluorescent product (green) upon cleavage by extracellular proteases. Application of 60
nM of the broad MMP inhibitor GM6001 (iMMP) was employed to prevent DQ-collagen
IV degradation by tumor cells (ref. 20) and serve as the negative control condition. Red
in right panels reflects F-actin staining. (d) Immunoblots of a representative experiment
with T84 cells, treated with the GCC ligand ST (1 μM, 5 min) or the cGMP analog 8-brcGMP (5 mM, 30 min). pS157-VASP and pS239-VASP, VASP phosphorylated at
Ser157 and Ser239, respectively; GAPDH, the loading control. (e) Bar graphs reflect

25

densitometric quantification of immunobands, normalized to respective loading
(GAPDH) and vehicle (PBS) controls (CTR), from experiments with T84 and HCT116
colon cancer cells treated as in d. Some conditions also received the peptide DT2 (5 μM,
30 min) to selectively and completely inhibit PKG-Iα activity (Ki, 12.5 nM; ref. 17). *, P
< 0.05, versus respective PBS control.
Fig. 2. GCC signaling through VASP is disrupted in colon cancer and its reconstitution
in vitro suppresses dynamic membrane regions. (a, upper panel) Representative IHC
images (magnification, 20x) of primary tumor (Tumor) and matched normal adjacent
tissue (NAT) from 7 patients with colorectal cancer. Tissues were stained with the
specific primary antibody (brown) and hematoxylin (blue, nuclei). The primary antibody
for VASP phosphorylated at Ser239 was clone 16C2 from Abcam. (a, middle panel)
Distribution (percentages indicated in boxes) of patients with different expression levels
(by staining intensity, as per Material and Methods) of the GCC pathway components.
The fraction of patients with upregulation (↑) or downregulation (↓) of the indicated
protein in tumors compared to respective NATs is provided in bottom. (a, lower panel)
Differential protein expression (the delta of staining intensity scores) in colorectal tumors
compared to matched NATs. *, P < 0.05; ***, P < 0.005 of tumors versus NATs.
pS157-VASP and pS239-VASP, VASP phosphorylated at Ser157 and Ser239,
respectively.

(b) Filopodia (arrows in upper-left slide) were imaged in cancer cell

colonies by DIC. (c) Invadopodia were imaged by confocal microscopy in single T84
cells, immunofluorescently stained with 4',6-diamidino-2-phenylindole (DAPI, for nuclei
in blue) and phalloidin (for F-actin in green). Boxes in cartoons on top indicate visual
planes in vertical (left panels) and horizontal (right panels) cross-sections from Z-stack
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images. In b-c, number and length of filopodia and invadopodia were quantified as
described in Material and Methods, and results are shown in bar graphs. Treatments (2 h)
were PBS (the vehicle control), ST (1 μM), or 8-bromo-cGMP (5 mM). *, P < 0.05,
versus respective PBS control.
Fig. 3. VASP Ser239 phosphorylation by GCC disrupts colon cancer cell filopodia. T84
cells were treated (with the PBS control or 1 μM ST to induce GCC signaling), imaged
and analyzed for quantification of filopodia as in Fig. 2b. Cancer cells stably expressed
the indicated MSCV-driven genes (see Material and Methods for details), including the
controls GFP and VASP, and VASP-S157A (S157A), VASP-S239A (S239A) and
VASP-AA (AA). Arrows in upper panels indicate representative filopodia. Bars, 10 µm.
*, P < 0.05 versus respective control.
Fig. 4. VASP Ser239 phosphorylation by GCC disrupts colon cancer cell invadopodia.
T84 cells were treated (with the PBS control or 1 μM ST to induce GCC signaling),
imaged and analyzed for quantification of invadopodia as in Fig. 2c. Cancer cells stably
expressed the indicated MSCV-driven genes (see Material and Methods for details),
including the control VASP, and VASP-S157A (S157A), VASP-S239A (S239A) and
VASP-AA (AA). Boxes in cartoons on left of top images indicate visual planes in
vertical (upper panels) and horizontal (bottom panels) cross-sections from Z-stacks. *, P
< 0.05 versus respective control.
Fig. 5. VASP Ser239 phosphorylation induces membrane protrusion retraction in colon
cancer cells. Fluorescently-tagged VASP constructs, GFP-VASP (VASP) and GFPVASP-S239A (S239A), were stably expressed in T84 cells as described in Material and
Methods. GCC signaling was induced with ST (1 μM), while PBS was the vehicle
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control. (a) Representative time course of a live cell experiment analyzing filopodial
kinetics by confocal microscopy, performed as detailed in Material and Methods.
Photographs reflect merged DIC and confocal microscopy images. (b) Representative 3D projections from live imaging (confocal microscopy) analyzing invadopodia in single
tumor cells plated on Matrigel scaffolds. Cartoons on top indicate visual vertical (left
panels) and basolateral en face (right panels) perspectives of 3-D reconstructions from Zstack images. (c) The length of filopodia following treatments for 15 min was quantified
as in Fig. 2b and expressed as percentages of respective PBS controls. (d) Quantification
of GFP-tagged VASP signals at filopodia tips from experiments shown in a. Results are
percentages of respective time 0 (before ST administration) controls. (e) Quantification
of GFP-tagged VASP signals in cell bodies (CB) and filopodia (F) before (CTR, time 0
control) and after ST (15 min) treatments, as shown in a. AU, arbitrary units. *, P < 0.05
versus respective control.
Fig. 6. VASP Ser239 phosphorylation inhibits the cleavage of DQ-collagen IV by colon
cancer cells. (a) T84 cells stably-expressing the indicated MSCV-driven genes (VASP,
the control; VASP-S157A, S157A; VASP-S239A, S239A; VASP-AA, AA) were treated
for 24 h with PBS, 1 μM ST or 60 nM of the broad MMP inhibitor GM6001 (iMMP),
imaged and analyzed by confocal microscopy for quantification of DQ-collagen IV
degradation as detailed in Material and Methods. Photographs (top) are merged DIC and
confocal microscopy images. Results (bottom) are expressed as arbitrary units (AU) of
the fluorescent signal from the cleaved collagen product. WT, wild-type T84 cells. *, P
< 0.05, versus respective PBS control.

(b) Proposed role of VASP in colorectal

carcinogenesis. During tumor progression, VASP phosphorylation at Ser239 (p-Ser239-
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VASP) is reduced, reflecting a dysregulated GCC pathway with interruption of cGMPmediated signaling, which promotes the formation of migratory membrane protrusions
and cancer cell invasion. Reconstitution of GCC and cGMP signaling, in turn, provides a
unique therapeutic opportunity to restrain the invasive tumor cell shape and prevent
metastasis.
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